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Since recombinant envelope glycoprotein E2 of hepatitis C virus (HCV) binds to CD81 on human and chimpanzee cells, it
has been suggested that CD81 may be a receptor for HCV. Humans and chimpanzees are the only species known to be
susceptible to HCV infection. E2 has been reported not to bind to CD81 of the African green monkey, mouse, or rat,
suggesting that binding of HCV to CD81 is species specific and may determine susceptibility to infection with HCV. We
investigated the interaction between E2 of HCV and CD81 of tamarins, a group of small New World monkeys frequently used
for the study of human viruses. Tamarins are not susceptible to HCV infection. Nonetheless, we found that three different
forms of HCV E2 (intracellular, secreted, and cell surface-displayed) bound more efficiently to recombinant tamarin CD81
than to human CD81, as determined by ELISA and immunofluorescence. The affinity of the interaction was approximately
10-fold higher for tamarin than for human CD81. Binding of E2 to CD81 on cultured or primary tamarin cells was demonstrated
by flow cytometry. In contrast to previous reports, there was also a low-affinity interaction between E2 and African green
monkey CD81. Thus, the HCV E2 interaction with CD81 is not limited to humans and chimpanzees and does not predict
susceptibility to HCV infection.INTRODUCTION
Hepatitis C virus (HCV) is an important cause of
chronic liver disease worldwide (Houghton, 1996). Hu-
mans and chimpanzees are the only species known to
be susceptible to HCV infection. The lack of a small
animal model and a reliable cell culture system has
hampered HCV research (Houghton, 1996). Tamarins, a
group of New World monkeys of the genus Saguinus, are
susceptible to several human viruses and have been
used in hepatitis research for decades (Deinhardt, 1978).
Tamarins are most likely the natural hosts of GB viruses
A and B, the viruses most closely related to HCV (Bukh
and Apgar, 1997; Simons et al., 1995). Although early
studies suggested that tamarins were susceptible to
non-A, non-B hepatitis (reviewed in Tabor, 1989), more
recent studies using HCV-specific assays indicate that
tamarins are not susceptible to HCV (Garson et al., 1997).
The factors responsible for host specificity and cell
tropism of HCV are largely unknown. However, it is
reasonable to assume that the envelope glycoproteins
are responsible for virus attachment and entry into sus-
ceptible cells. HCV is a member of the Flaviviridae family
of viruses. It has a lipid envelope into which two enve-
lope glycoproteins (E1 and E2) are inserted as het-
erodimers (reviewed in Dubuisson, 1999). The envelope
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358glycoproteins of HCV have been expressed in mamma-
lian cells. However, when expressed as recombinant
proteins, the majority of E1 and E2 is misfolded. Further-
more, E1 and E2 are retained in the endoplasmic retic-
ulum (ER), suggesting that HCV, like other members of
the Flaviviridae family, buds from this compartment. Re-
tention in the ER can be overcome by deleting the trans-
membrane domain of E2, which results in secretion of
soluble E2 protein (Spaete et al., 1992), or by replacing it
with the transmembrane domain of a protein that is
normally transported to the cell surface, which results in
cell surface display of E2 (Cocquerel et al., 1998; Forns et
al., 1999, 2000). The glycosylation pattern of secreted E2
differs from that of intracellular E2 (Flint et al., 2000;
Spaete et al., 1992). The composition and arrangement of
carbohydrate chains on E2 of infectious HCV is not
known. Thus, it is difficult to establish whether any re-
combinant E2 protein has the appropriate conformation
or glycosylation pattern.
Two candidate cellular receptors for HCV have re-
cently been proposed, the LDL receptor (Agnello et al.,
1999) and CD81 (Pileri et al., 1998). Originally, Rosa et al.
(1996) showed that recombinant E2 of HCV could bind to
human or chimpanzee cells, and that the binding could
be inhibited by serum from chimpanzees that were pro-
tected from HCV infection after vaccination with recom-
binant E1/E2 proteins. The molecule responsible for
binding E2 was subsequently identified as CD81 (Pileri et
al., 1998). CD81 is a member of the tetraspannin family,
and thus has two extracellular loops. The binding site for
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359HCV E2 BINDS TO TAMARIN CD81HCV E2 protein was mapped to the large extracellular
loop (LEL), also designated second extracellular loop
(EC2) (Flint et al., 1999; Pileri et al., 1998). Recombinant
human LEL expressed in E. coli binds to HCV E2 (Flint et
al., 1999).
The majority of the CD81 molecule is highly conserved
among mammalian species. However, the C-terminus of
the LEL contains species-specific differences. The
mouse and human CD81 LEL differ from each other at 17
of the 89 amino acid positions, whereas the African
green monkey and human LEL differ from each other at
only four amino acid positions (Fig. 1). Of the two pub-
lished chimpanzee CD81 sequences, one is identical to
that of humans and one differs by a single amino acid
(Flint et al., 1999; Pileri et al., 1998). HCV E2 protein has
been reported to bind CD81 on human or chimpanzee
cells, but not on African green monkey or rat cells (Flint
et al., 1999). Furthermore, recombinant human, but not
mouse, LEL could bind to HCV particles in serum (Pileri
et al., 1998). These data suggested that CD81 binding
correlated with susceptibility to HCV. However, the num-
ber of species studied so far is limited. To evaluate
tamarins as potential hosts for HCV/GB virus B chimeric
virus constructs (Bukh et al., 1999), we investigated the
binding of HCV E2 to tamarin CD81.
RESULTS
Sequence of tamarin CD81 differed from that of
human and African green monkey
The cDNA sequence of CD81 LEL was determined for
two tamarin species, S. oedipus and S. mystax. The LEL
of the two tamarin species differed at a single nucleotide
position, but the deduced amino acid sequences were
identical (Fig. 1). Tamarin LEL (89 amino acids) differed
from human and African green monkey LEL at five and
six amino acid positions, respectively, and from mouse
LEL at 17 amino acid positions.
HCV E2 had higher affinity for tamarin CD81 LEL than
for human CD81 LEL
An ELISA assay was developed in which purified HCV
E2 protein was coated onto the solid phase. Binding of
thioredoxin-LEL fusion protein (trx-LEL) was detected
with a mouse monoclonal antibody (MAb) to thioredoxin
and an alkaline phosphatase-labeled anti-mouse anti-
FIG. 1. Alignment of amino acid sequences of human, chimpanzee,
identical to human CD81. Capital letter: amino acid different from humserum. Two different forms of purified E2 were used,
secreted E2388–664 (Abbott) (Lesniewski et al., 1995) andintracellular E2383–715 (Chiron) (Petracca et al., 2000), since
ifferent forms of E2 are reported to have different CD81
inding properties (Flint et al., 2000; Forns et al., 2000).
uman, tamarin, and African green monkey trx-LEL each
ound to both E2 preparations (Fig. 2). Tamarin LEL-
inding was more efficient than human LEL-binding to
green monkey, tamarin, and mouse LEL of CD81. Dash: amino acid
1. *: According to Pileri et al. (1998).
FIG. 2. Binding of human, tamarin, African green monkey, or mouse
recombinant trx-LEL of CD81 or thioredoxin alone to secreted or intra-
cellular HCV E2 preparations as determined by ELISA. (A) Coated
protein is secreted E2388–664 (Abbott). (B) Coated protein is intracellular
E2383–715 (Chiron).
cd
360 ALLANDER ET AL.both forms of E2, whereas African green monkey LEL
displayed less-efficient binding. Mouse LEL or thiore-
doxin alone expressed from the same vector did not bind
to E2. The affinities of the E2 interaction with CD81 of the
three different primate species were estimated by a
competitive ELISA (Rath et al., 1988), in which soluble E2
at various concentrations was added to the trx-LEL be-
fore performing the ELISA. This experiment confirmed
that tamarin LEL had higher affinity than human LEL for
either form of E2, and that African green monkey LEL had
a low, but detectable, affinity for each form of E2 (Table
1). The intracellular E2383–715 (Chiron) had higher affinity
than secreted E2388–664 (Abbott) for CD81 LEL of all three
primate species tested.
To determine whether a particular tamarin-specific
amino acid substitution accounts for the enhanced E2
affinity of tamarin CD81 LEL, we cloned and expressed
recombinant trx-LEL molecules having each of four sin-
gle tamarin-specific substitutions introduced into the hu-
man sequence. The fifth substitution, D196E, was not
analyzed, since this is also present in the African green
monkey CD81 LEL and was studied in that context (Hig-
ginbottom et al., 2000) and found not to affect E2 binding.
No single substitution was able to increase the affinity of
the human LEL to that of tamarin LEL (Fig. 3). The T163S
substitution, both alone and in combination with N180S,
enhanced E2 binding to some extent, but not to the level
of the complete tamarin LEL. The other substitutions
either did not affect or slightly reduced E2 binding. Thus,
a combination of two to five of the substitutions must be
required for the increased E2 affinity of tamarin CD81
LEL compared to that of the human molecule.
CD81 LEL of human, tamarin, and African green
monkey origin bound to HCV E2 expressed on the
cell surface
We recently characterized E2384–661 expressed on the
cell surface and found it to be reactive with conforma-
tion-sensitive MAbs and with human CD81 LEL (Forns et
TABLE 1
Relative Affinities of Secreted E2388-664 (Abbott) and Intracellular
E2383-715 (Chiron) for Recombinant CD81 LEL of Human, Tamarin, or
African Green Monkey Origin
CD81 LEL
Secreted E2388-664
(Abbott)
Intracellular E2383-715
(Chiron)
Tamarin 1028 1028.5
Human 1026.5 1027.5
African green monkey ,1026 a 1026
a A 25% inhibition was obtained with 1026 M soluble E2; a higher
oncentration was not tested.al., 2000). In contrast, E2384–715 expressed similarly had
decreased reactivity with one conformation-sensitiveMAb and with human CD81 LEL. Therefore, we also
analyzed binding of the different primate LEL to the
well-characterized and apparently well-folded E2384—661
form that was transiently expressed on the surface of
Huh-7 cells. Cells were not fixed and were incubated
with trx-LEL and antibodies directly in the culture dish so
that only surface-displayed E2 was accessible to the
trx-LEL. Bound trx-LEL protein was detected with a
mouse MAb to thioredoxin, followed by fluorescein iso-
thiocyanate (FITC)-labeled anti-mouse immunoglobulin.
Human or tamarin LEL bound efficiently to the cells
expressing E2, as detected by both immunofluorescence
FIG. 3. Effect of single tamarin-specific amino acid substitutions in
the human trx-LEL of CD81 on binding to secreted E2388–664 (Abbott) as
etermined by ELISA.
FIG. 4. Binding of human, tamarin, African green monkey, or mouse
recombinant trx-LEL to Huh-7 cells expressing E2 from the plasmid
pE2surf-661, as determined by immunofluorescence microscopy. Left
panel: Cells are stained before fixation so that E2 on the cell surface
only is available for LEL binding. Right panel: Cells are stained after
acetone fixation so that both intracellular and cell surface-displayed E2
are available for LEL binding.
b
a
n
t
M
(
b
i
t
o
E
a
M
c
l
C
f
b
o
b
a
i
w
a
m
m
s
t
L
p
H
361HCV E2 BINDS TO TAMARIN CD81microscopy (Fig. 4) and flow cytometry. Although nearly
saturating concentrations of trx-LEL were used, tamarin
LEL resulted in brighter fluorescence than did human
LEL. By flow cytometry, cells incubated with mouse LEL
were considered negative, whereas reaction with tama-
rin LEL yielded 35% positive cells with mean fluores-
cence intensity (FI) of 1202 compared to 28% positive
cells with mean FI of 867 after incubation with human
LEL. Incubation with African green monkey LEL resulted
in 2.2% positive cells with mean FI of 218. Numbers refer
to a single experiment, but similar results were obtained
in a repeat experiment. Additionally, a few cells that had
reacted with African green monkey LEL were identified
by immunofluorescence microscopy (Fig. 4). Since it was
reported that CD81 has higher affinity for intracellular E2
than for secreted E2 (Flint et al., 2000), we analyzed cells
after fixation with acetone, so that intracellular E2 was
also accessible. This resulted in increased fluorescence
of the cells incubated with African green monkey LEL
(Fig. 4). Negative control cells transfected with a plasmid
expressing HCV E1 did not bind LEL of any of the four
species tested (data not shown).
HCV E2 protein bound to CD81 on tamarin lymphoid
cells
To verify that CD81 naturally expressed on cells gives
results comparable to those obtained with recombinant
LEL fusion proteins, we tested tamarin and African green
monkey cell lines as well as tamarin peripheral blood
mononuclear cells (PBMC) for E2 binding by flow cytom-
etry, using published methods (Flint et al., 1999; Higgin-
ottom et al., 2000; Rosa et al., 1996). Human PBMC and
mouse lymphoid cell line were used as positive and
egative controls, respectively. The presence of CD81 on
he cells was first confirmed by staining with anti-CD81
Abs (Fig. 5). Human PBMC bound secreted E2388–664
(Abbott) and the interaction was inhibited by anti-CD81
MAb JS64 (Fig. 6A). The interaction could also be inhib-
ited by human and tamarin trx-LEL, but not mouse
trx-LEL (data not shown). The mouse B-cell lymphoma
line WEHI-231 did not bind secreted E2388–664 (Abbott)
Fig. 6B).
The tamarin B-lymphocyte line B95-8 was tested for
inding of secreted E2388–664 (Abbott) and for binding of
ntracellular E2383–715 (Chiron) (Figs. 6C and 6D, respec-
ively). Each E2 form bound to these cells. A greater shift
f fluorescence intensity was seen with the intracellular
2, consistent with its higher affinity for CD81. The inter-
ction was significantly inhibited (.60%) by anti-CD81
Ab JS64, although not to the same extent as for human
ells using the same reagent concentrations. This was
ikely the result of the higher affinity of E2 for tamarinD81, possibly combined with lower affinity of MAb JS64
or tamarin CD81. It cannot be excluded, however, that E2inds not only to CD81 but also to additional molecules
n these cells.
In addition, tamarin (S. mystax) PBMC were tested for
inding of secreted E2388–664 (Abbott). Results from two
nimals are shown in Figs. 6E and 6F. The average shift
n fluorescence intensity was greater than that observed
ith human PBMC. The interaction was inhibited by
nti-CD81 MAb JS64 (Fig. 6F) and tamarin, but not
ouse, trx-LEL (data not shown).
Confirming the low-affinity interaction of African green
onkey CD81 with E2 was technically more difficult,
ince the flow cytometry assay is less sensitive than is
he ELISA or immunofluorescence assay utilizing trx-
EL. African green monkey-derived COS-7 cells were
reviously reported not to bind E2 (Flint et al., 1999;
igginbottom et al., 2000). In our studies, these cells
displayed only minimal binding of intracellular or se-
creted E2 (data not shown). However, a cell line derived
from primary African green monkey kidney cells (AGMK)
(Potash et al., 1997) expressed a level of CD81 similar to
that of COS-7 cells as determined by staining with MAb
JS-81 (Fig. 5). This cell line showed weak but significant
binding of intracellular E2383–715 (Chiron) that was specific
because binding was inhibited by anti-CD81 MAb JS64 or
human, but not mouse, trx-LEL (Figs. 7A–7C). Minimal
binding, if any, was seen with secreted E2388–664 (Abbott),
consistent with its lower affinity for CD81 (Fig. 7D).
DISCUSSION
Without a cell culture system it is difficult to confirm
the role of the E2–CD81 interaction in virus entry into
cells. The original finding that CD81 molecules of human
or chimpanzee, but not of mouse, origin bind to E2
suggested that CD81 binding may determine species
specificity of HCV infection (Pileri et al., 1998). African
green monkey CD81, differing by only four amino acids
from human CD81, was subsequently reported not to
bind E2, which supported the concept that E2 binds only
to CD81 of species susceptible to HCV (Flint et al., 1999;
Higginbottom et al., 2000).
Our results are at variance with the concept that CD81
binding predicts susceptibility to HCV, since HCV E2
binds strongly to tamarin CD81 and tamarins are appar-
ently not susceptible to HCV infection. A major concern
about studies of this kind is how faithfully recombinant
E2 protein represents E2 in the E1/E2 heterodimers of
the virus particle. In fact, only one report so far has
demonstrated that hepatitis C virions bind to CD81, and
in that case recombinant trx-LEL, rather than native
CD81, was tested (Pileri et al., 1998). We addressed this
problem by using three different well-characterized prep-
arations of E2, one secreted (Lesniewski et al., 1995),
one intracellular (Petracca et al., 2000), and one dis-
played on the surface of cells (Forns et al., 2000). Al-
though the affinity for CD81 differed among the E2 prep-
g
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362 ALLANDER ET AL.arations, they gave essentially the same result with re-
gard to the species differences, i.e., E2 bound more
efficiently to tamarin CD81 than to human CD81, and
there was a low-affinity interaction with the African green
monkey CD81.
The affinity data were collected to compare the bind-
FIG. 5. CD81 expression of various cells used for the HCV E2-binding
raph. (A) Human PBMC stained with MAb 1.3.3.22. (B) Mouse B-cell lym
ith MAb JS-81. (D) Tamarin PBMC stained with MAb 1.3.3.22. (E) African
idney cells (AGMK) stained with MAb JS-81.ing affinities of CD81 from the different primates. The
accuracy of the method in absolute numbers is moderate(Rath et al., 1988). However, data agreed well with pre-
viously reported affinity measurements of the E2–CD81
interaction. Petracca et al. (2000) calculated the affinity of
intracellular E2383–715 (Chiron) for purified human LEL as
1.8 3 1029 M, noting that the affinity for human trx-LEL is
five to 10 times lower. Rosa et al. (1996) estimated the
s. Unstained cells are represented by solid graph, stained cells by line
cells WEHI-231 stained with MAb 2F7. (C) Tamarin B95-8 cells stained
monkey COS-7 cells stained with MAb JS-81. (F) African green monkeystudie
phomabinding affinity of secreted E2384–715 to human MOLT-4
cells as approximately 1028 M. Flint et al. (2000) reported
s
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363HCV E2 BINDS TO TAMARIN CD81that intracellular E2 has higher affinity for CD81 than
does secreted E2, and suggested that variation in glyco-
sylation may account for this difference. The present
results are consistent with those of Flint et al. (2000),
ince the intracellular E2 had higher affinity than se-
reted E2 for CD81 of all three primate species tested. It
FIG. 6. Binding of E2 to human, mouse, or tamarin cells measured by
D)] at 10 mg/ml followed by MAb H53 and PE-anti-mouse IgG1 MAb (
the absence of E2 (solid graph). Inhibition of E2 binding by preincubat
(E) and (F) show PBMC from two different tamarins. (A) Human PBMC
incubated with intracellular E2383–715 (Chiron). (E) Tamarin PBMC (S. myhould be noted, however, that the two purified E2 prep-
rations used in the present study were derived fromdifferent HCV strains; thus, the sequence, as well as the
C-terminal truncation site, differed slightly (Lesniewski et
al., 1995; Petracca et al., 2000), which could also affect
the affinity for CD81.
Analysis of the substitutions distinguishing tamarin
CD81 from human CD81 showed that the T163S substi-
ometry. Cells were incubated with secreted E2388–664 (Abbott) [all except
ne), and compared with cells stained with the same antibodies but in
he cells with anti-CD81 MAb JS64 is indicated by dotted line. Graphs
use WEHI-231 cells. (C) Tamarin B95-8 cells. (D) Tamarin B95-8 cells
4, inhibition not tested). (F) Tamarin PBMC (S. mystax 863).flow cyt
solid li
ion of ttution resulted in increased affinity for E2, whereas the
three other individual tamarin-specific substitutions did
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364 ALLANDER ET AL.not enhance E2 binding. This is analogous to the finding
that a T 3 A substitution present at the same position
(163) in African green monkey CD81 enhances E2 bind-
ing (Higginbottom et al., 2000). Therefore, a combination
involving two or more substitutions must be required to
maximize the affinity of tamarin CD81 for E2.
The present demonstration that African green monkey
CD81 binds E2 contrasts with previous reports, in which
the absence of binding is described in great detail using
both flow cytometry and ELISA (Flint et al., 1999; Higgin-
bottom et al., 2000). The discrepancy may be explained
by the fact that the previous studies were done with
secreted E2 only, and that a less-sensitive ELISA assay
was used. In our studies the ELISA assay was far more
sensitive when wells were coated with E2 instead of the
LEL fusion protein as published previously (Higginbot-
tom et al., 2000). The flow cytometry assay is clearly less
sensitive than ELISA for low-affinity interactions. By flow
FIG. 7. Binding of E2 to African green monkey kidney cells (AGMK)
(Chiron) [all except (D)] at 10 mg/ml followed by MAb H53 and PE-anti-
antibodies in the absence of E2 (solid graph). Graphs (A)–(C) show th
not mouse trx-LEL. (A) Preincubation of the cells with anti-CD81 MAb JS
trx-LEL (dotted line) (C) Preincubation of the E2 protein with mouse trcytometry, we found that only intracellular E2383–715 (Chi-
ron) but not secreted E2388–664 (Abbott) bound to African
i
bgreen monkey cells, which is in agreement with the
previous reports.
Whether the HCV E2–CD81 interaction has any rele-
vance for virus entry into cells is still an open question.
The poor internalization of CD81 and binding of E2 to
cells that do not express CD81 led Petracca et al. (2000)
o suggest the presence of a coreceptor. Takikawa et al.
2000) used a cell-fusion assay and found that CD81
lone was not sufficient for fusion. Immunomodulatory
ffects of CD81 engagement were previously described
Flint et al., 1999) and this may well be the main function
f the E2–CD81 interaction. The preferential binding of
ntracellular E2 to CD81 leads us to speculate that ex-
ess E2 is released from lysed cells and that this re-
eased E2 is more biologically relevant for CD81 binding
han is E2 in virions. On the other hand, if CD81 actually
s a receptor for HCV, the present data suggest that lack
f attachment to CD81 is not the factor preventing HCV
red by flow cytometry. Cells were incubated with intracellular E2383–715
IgG1 MAb (solid line), and compared with cells stained with the same
nteraction could be inhibited by anti-CD81 MAb JS64, and human but
dicated by dotted line. (B) Preincubation of the E2 protein with human
dotted line). (D) Cells were incubated with secreted E2388–664 (Abbott).measu
mouse
at the infection of tamarins and African green monkeys. The
lock to infection may appear at the level of coreceptor
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365HCV E2 BINDS TO TAMARIN CD81or postentry events. In the latter case, construction of
HCV/GB virus B chimeric viruses may provide a useful
approach to the study of HCV in a small animal model.
Following the initial submission of this report, a study
by Meola et al. (2000) was published, which also dem-
nstrated that tamarin CD81 binds to HCV E2 with a
igher affinity than does human CD81.
MATERIALS AND METHODS
CV E2 preparations
Purified secreted E2 (a.a. 388–664) (Lesniewski et al.,
995) was kindly provided by Dr. I. K. Mushahwar (Abbott
aboratories, North Chicago, IL). Purified intracellular E2
a.a. 383–715) (Petracca et al., 2000; Spaete et al., 1992)
was kindly provided by Dr. M. Houghton (Chiron Corpo-
ration, Emeryville, CA). The E2 protein (a.a. 384–661)
expressed on the surface of Huh-7 cells was described
elsewhere (Forns et al., 2000). Cells were transfected
with the plasmid pE2surf-661, encoding a.a. 384–661 of
E2 cloned into pDisplay (Invitrogen, Carlsbad, CA), in
frame between a signal sequence and the transmem-
brane domain of human platelet-derived growth factor
receptor. All three E2 proteins were derived from HCV-H
or HCV-1, which are related HCV genotype 1a strains,
and thus differed slightly from each other in amino acid
sequence.
Cloning, expression, and purification of CD81 LEL
The LEL of CD81 was expressed in fusion with thiore-
doxin, as previously described (Pileri et al., 1998). RNA
was extracted from the following cells or tissues using
Trizol (Gibco BRL, Gaithersburg, MD): human hepatoma
cells (Huh-7), liver homogenate of a tamarin (S. oedipus),
and COS-7 cells (African green monkey kidney). Mouse
liver RNA was purchased from Stratagene (La Jolla, CA).
Sequence encoding LEL was amplified by RT-PCR with
the primers CD81-19S and CD81-693AS (Table 2). PCR
products were sequenced directly. The nearly complete
T
Primers Used for Amplification of CD81-E
Primer Sequence
CD81-19S ACCAAGTGCATC
CD81-693AS CCGGATGCCACA
For-tEC2 GGCGGGGGTGG
Rev-tEC2 CCCCAAGCTTTCA
For-mEC2 GGCGGGGGTGG
Rev-mEC2 CCCCAAGCTTTCA
Note. For-tEC2, Rev-tEC2, For-mEC2, and Rev-mEC2 are modification
f DNA encoding tamarin and mouse LEL respectively. African greencDNA sequence of S. oedipus CD81 (nucleotides 40–672
of the open reading frame) was deposited in GenBank(Accession No. AF274885). For cloning, a second round
of PCR was performed using primers For-hEC2 and Rev-
hEC2 (Pileri et al., 1998) or species-specific modifica-
tions thereof (Table 2). The PCR products were digested
with XhoI and HindIII and ligated to the vector pThioHisC
(Invitrogen). Inserts were sequenced and the constructs
were transformed into E. coli TOP-10 (Invitrogen) by elec-
troporation. For expression of the fusion protein, 1 ml of
an overnight culture of a single colony containing an LEL
construct or the vector only was inoculated into 100 ml
Luria Bertani liquid with 100 mg/ml ampicillin and grown
at 37°C until the OD600 was approximately 0.5. b-D-Iso-
propyl-thiogalactopyranoside was added to 1 mM and
cells were cultured for an additional 3.5 h at 37°C. Cells
were pelleted by centrifugation; dissolved in 10 ml of 500
mM NaCl, 20 mM sodium phosphate buffer, pH 7.8;
freeze-thawed four times; and sonicated twice for 15 s.
The bacterial lysate was treated with DNase I and cel-
lular debris was pelleted by centrifugation. The superna-
tant was filtered through a 45-mm filter, mixed with 2 ml
of a nickel-chelating Sepharose resin (ProBond; Invitro-
gen), and incubated for 15 min on ice. The resin was
washed 10 times with 8 ml of 500 mM NaCl, 20 mM
sodium phosphate buffer, pH 6.0, by centrifugation at 200
g for 2 min. Bound protein was eluted with 5 ml of 200
mM imidazole, dialyzed against PBS, and concentrated
to 1 ml using a centrifugal filter device (Centricon; Milli-
pore, Bedford, MA). The identity of the fusion protein was
confirmed by SDS–PAGE analysis and Western blot with
antibodies to thioredoxin (Anti-Thio monoclonal antibody;
Invitrogen) or CD81 (anti-CD81 polyclonal goat serum;
Santa Cruz Biotechnology, Santa Cruz, CA).
For construction of trx-LEL proteins having single
tamarin-specific substitutions introduced into the human
sequence, fusion PCR with vector-specific primers and
mutagenized primers covering the codon of interest was
carried out using the cloned human LEL as template. The
resulting fusion PCR products were digested with XhoI
and HindIII and subsequently cloned and expressed as
Sequences of Different Animal Species.
CCTG
GCAC
GGGGTGGAGGCTCGAGCTTTGTCAACAAAGACC
TTCCCGGAGAAGAGCTCATCG
GGGGTGGAGGCTCGAGCTTCGTAAACAAAGACC
TTCCCAGAGAAGAGCTCATCG
e primers For-hEC2, and Rev-hEC2 (Pileri et al., 1998) for amplification
LEL DNA was amplified using For-hEC2 and Rev-tEC2.ABLE 2
ncoding
AAGTA
GCACA
ATCCG
CAGC
ATCCG
CAGCdescribed above. For extraction and purification of trx-
LEL an alternative osmotic shock purification protocol
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366 ALLANDER ET AL.was used for all proteins shown in Fig. 3. After induction
as above, cells were spun down and dissolved in 20 ml
ice-cold 20 mM Tris–HCl, pH 8, 2.5 mM EDTA, 20%
sucrose; incubated for 10 min; pelleted; and dissolved in
20 ml ice-cold 20 mM Tris–HCl, pH 8, 2.5 mM EDTA, after
which they were again incubated for 10 min and pelleted.
The supernatant was filtered, precipitated with 30% am-
monium sulfate, centrifuged at 16,000 g, and the protein
pellet was dissolved in PBS.
Binding of CD81 LEL to HCV E2 analyzed by ELISA
Binding of recombinant trx-LEL to purified E2 was
studied by ELISA, and the affinity of the interaction was
estimated by inhibition with various concentrations of
soluble E2 protein (Rath et al., 1988). A microtiter plate
(Costar 3690; Costar, Cambridge, MA) was coated with
purified recombinant E2388–664 (Abbott Laboratories) or
E2383–715 (Chiron) at 2 mg/ml overnight at 4°C, and subse-
quently blocked with 5% nonfat dry milk for 1 h at room
temperature. The different trx-LEL preparations were
added at twofold dilutions and incubated for 2 h at room
temperature. Bound trx-LEL was detected by incubating
with a mouse MAb to thioredoxin (Invitrogen) for 1 h at
room temperature followed by alkaline phosphatase-
conjugated anti-mouse IgG antiserum (Pierce, Rockford,
IL) for 1 h at room temperature, and substrate for 30 min.
For affinity determination, samples were tested at a di-
lution giving approximately 50% saturation in the above-
mentioned ELISA. Diluted thioredoxin–LEL preparations
with or without added soluble E2 (at 10-fold dilutions,
maximum concentration 60 mg/ml) were added to the
ells, and the ELISA was performed as described above.
he reduction of optical density in the presence of sol-
ble E2 and, subsequently, the concentration needed for
50% reduction were calculated.
inding of CD81 LEL to E2-expressing cells analyzed
y immunofluorescence microscopy and flow
ytometry
Huh-7 cells cultured on chamber slides or in six-well
lates were transfected with the plasmid pE2surf-661 or
E1surf-347 (Forns et al., 2000) using Superfect Reagent
(Qiagen, Valencia, CA). Plasmid pE2surf-661 encodes
a.a. 384–661 of E2 cloned into pDisplay (Invitrogen).
Plasmid pE1surf-347 encodes HCV envelope protein E1
(a.a. 192–347) in the same vector and was used as a
negative control. Cells were analyzed 48 h after trans-
fection. For surface staining, cells were washed with
wash buffer (WB: PBS, 1% fetal calf serum, 0.05% sodium
azide) and stained directly. For intracellular staining,
cells were fixed and permeabilized with acetone before
staining. Recombinant trx-LEL preparations of the differ-
ent species (or only thioredoxin expressed from the
same vector and purified in the same way) were added at
2 mg/ml. Slides were incubated for 1 h at room temper-ature, washed with WB, and incubated with a mouse
MAb to thioredoxin (Invitrogen) for 1 h, followed by a
FITC-conjugated antibody to mouse IgG for 1 h. After
washing, unfixed cells were fixed with acetone, mounted,
and examined by fluorescence microscopy. For flow cy-
tometry, stained, unfixed cells were scraped off the six-
well plate and analyzed in a FACScan instrument (Bec-
ton-Dickinson, San Jose, CA). Data were processed us-
ing Cellquest software (Becton-Dickinson).
Binding of E2 to CD81-expressing cells analyzed by
flow cytometry
The following cells were tested for E2 binding: tamarin
cell line B95-8 (Epstein–Barr virus-transformed B lympho-
cytes of S. oedipus, ATCC CRL-1612; ATCC, Manassas,
VA), mouse B-cell lymphoma line WEHI-231 (ATCC CRL-
1702), African green monkey kidney cell line COS-7, Af-
rican green monkey kidney cell line AGMK (Potash et al.,
1997), and human and tamarin PBMC. Cells grown in
suspension were harvested by centrifugation and
washed once in WB before staining. COS-7 and AGMK
cells were scraped off the flask to avoid trypsin, or
stained attached to a six-well culture plate using the
same reagent concentrations as above, and scraped off
the plate before flow cytometry analysis. Human and
tamarin PBMC were isolated from 3 to 10 ml of fresh
heparinized blood using Ficoll–Paque Plus (Amersham
Pharmacia Biotech, Piscataway, NJ). For tamarin cells,
additional lysis of remaining erythrocytes with ammo-
nium chloride lysis buffer for 3 min was necessary. De-
tection of CD81 on the cells was done using standard
flow cytometry techniques and the anti-human CD81
MAbs 1.3.3.22 (Santa Cruz Biotechnology) or JS-81
(Pharmingen, San Diego, CA), or hamster anti-mouse
CD81 MAb 2F7 (Pharmingen).
For the E2-binding assay, approximately 1 3 106 cells
ere incubated for 1 h at room temperature with purified
2 [secreted E2388–664 (Abbott) or intracellular E2383–715
(Chiron) at 10 mg/ml in 100 ml WB]; negative control cells
ere incubated in WB only. Cells were washed twice by
entrifugation in WB and incubated with anti-E2 mono-
lonal antibody H53 (Cocquerel et al., 1998) (provided by
r. J. Dubuisson) at 5 mg/ml for 1 h at room temperature,
followed by two washes and incubation with a phyco-
erythrin-labeled rat MAb to mouse IgG1 (Becton Dickin-
son Immunocytometry Systems, San Jose, CA). The use
of a monoclonal anti-IgG1 secondary antibody enabled
confirmation of the E2–CD81 binding specificity by block-
ing with anti-CD81 MAb JS64 (Coulter Cytometry, Miami,
FL) that belongs to subclass IgG2a. Cells were finally
washed twice and resuspended in wash buffer. The
difference in fluorescence intensity between cells incu-
bated with or without E2 was the readout, and this was
previously shown to represent E2 binding (Flint et al.,
1999; Rosa et al., 1996). Confirmation of E2 binding spec-
t367HCV E2 BINDS TO TAMARIN CD81ificity was done by preincubating the cells with anti-CD81
MAb JS64 at 5 mg/ml or preincubating the E2 protein with
rx-LEL at 10 or 20 mg/ml for 30 min.
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